The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
Abstract
Purpose: In patients with metastatic breast cancer (MBC), nab-paclitaxel produced significantly higher antitumor activity compared with patients who received solvent-based paclitaxel. This phase II study examined the antitumor activity and safety of weekly and every 3 week (q3w) nab-paclitaxel compared with docetaxel as first-line treatment in patients with MBC. Patients and Methods: In this randomized, multicenter study, patients (N = 302) with previously untreated MBC received nab-paclitaxel 300 mg/m 2 q3w, 100 mg/m 2 weekly, or 150 mg/m 2 weekly or docetaxel 100 mg/m 2 q3w. Results: nab-Paclitaxel 150 mg/m 2 weekly demonstrated significantly longer progression-free survival (PFS) than docetaxel by both independent radiologist assessment (12.9 v 7.5 months, respectively; P = .0065) and investigator assessment (14.6 v 7.8 months, respectively; P = .012). On the basis of independent radiologist review, both 150 mg/m 2 (49%) and 100 mg/m 2 (45%) weekly of nab-paclitaxel demonstrated a higher overall response rate (ORR) than docetaxel (35%), but this did not reach statistical significance. This trend was supported by statistically significant investigator ORR for both weekly nab-paclitaxel doses versus docetaxel. nab-Paclitaxel q3w versus docetaxel was not different for PFS or ORR. On the basis of both the independent radiologist and investigator review, disease control rate was significantly higher for patients receiving either dose of weekly nab-paclitaxel compared with docetaxel. Grade 3 or 4 fatigue, neutropenia, and febrile neutropenia were less frequent in all nab-paclitaxel arms. The frequency and grade of peripheral neuropathy were similar in all arms. Conclusion: This randomized study in first-line MBC demonstrated superior efficacy and safety of weekly nab-paclitaxel compared with docetaxel, with a statistically and clinically significant prolongation of PFS (> 5 months) in patients receiving nab-paclitaxel 150 mg/m 2 weekly compared with docetaxel 100 mg/m 2 q3w.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Self-citationDesai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Albumin-bound paclitaxel: a next-generation taxane
Gradishar, W. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1041 · Cited by 712
Self-citationSeidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
O’Shaughnessy, J. A., Blum, J., Moiseyenko, V., Jones, S. E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.-U., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012281104865 · Cited by 304
Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Desai, N. P., Trieu, V., Hwang, L. Y., Wu, R., Soon-Shiong, P., & Gradishar, W. J. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32830f9046 · Cited by 205
Self-citationTaxanes for adjuvant treatment of early breast cancer
Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., & Nowak, A. K. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004421.pub2 · Cited by 195
Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0344 · Cited by 182
Blum, J. L., Savin, M. A., Edelman, G., Pippen, J. E., Robert, N. J., Geister, B. V., Kirby, R. L., Clawson, A., & O'Shaughnessy, J. A. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.049 · Cited by 172
Self-citationHenderson, I. C., & Bhatia, V. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.7.919 · Cited by 102
Nanoparticle Albumin–Bound Paclitaxel for Metastatic Breast Cancer
Harries, M., Ellis, P., & Harper, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.002 · Cited by 100
Rivera, E., Mejia, J. A., Arun, B., Adinin, R. B., Walters, R. S., Brewster, A. M., Broglio, K. R., Yin, G., Esmaeli, B., Hortobágyi, G. N., et al. (2008) · Cancer · doi:10.1002/cncr.23321 · Cited by 99
Taxanes in breast cancer: An update
Conlin, A. K., & Seidman, A. D. (2007) · Current Oncology Reports · doi:10.1007/bf02951422 · Cited by 48
Verrill, M. W., Lee, J., Cameron, D., Agrawal, R. K., Coleman, R. E., McAdam, K., Wardley, A. M., Bowman, A., Ferrigan, L., & Yellowlees, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba1005 · Cited by 46
McKenzie, A. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91893-1 · Cited by 40
Cited by
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Self-citationImpact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Metadata
- Authors
- Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-01
- Volume
- 27
- Issue
- 22
- Pages
- 3611-3619
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117972559
- Cited by
- 341
- References
- 19
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.